Calcineurin-inhibitor minimization protocols in heart transplantation
Tóm tắt
Từ khóa
Tài liệu tham khảo
John, 2001, Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy, Ann Thorac Surg, 72, 440, 10.1016/S0003-4975(01)02784-9
Taylor, 2006, International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006, J Heart Lung Transplant, 25, 869, 10.1016/j.healun.2006.05.002
Bloom, 2006, Kidney disease after heart and lung transplantation, Am J Transplant, 6, 671, 10.1111/j.1600-6143.2006.01248.x
Ojo, 2003, Chronic renal failure after transplantation of a nonrenal organ, N Engl J Med, 349, 931, 10.1056/NEJMoa021744
Alam, 2007, The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR), Am J Transplant, 7, 461, 10.1111/j.1600-6143.2006.01640.x
Senechal, 2004, End-stage renal failure and cardiac mortality after heart transplantation, Clin Transplant, 18, 1, 10.1111/j.1399-0012.2004.00105.x
Hunt, 1987, Results of immunoconversion from cyclosporine to azathioprine in heart transplant recipients with progressive nephrotoxicity, Transplant Proc, 19, 2522
Kobashigawa, 1998, A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators, Transplantation, 66, 507, 10.1097/00007890-199808270-00016
Keogh, 2004, Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial, Circulation, 110, 2694, 10.1161/01.CIR.0000136812.90177.94
Eisen, 2003, Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients, N Engl J Med, 349, 847, 10.1056/NEJMoa022171
Kobashigawa, 2006, Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report, Am J Transplant, 6, 1377, 10.1111/j.1600-6143.2006.01290.x
Rosenberg, 2005, Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation, J Heart Lung Transplant, 24, 1327, 10.1016/j.healun.2004.08.003
Cantarovich, 2004, Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction, Transplantation, 78, 779, 10.1097/01.TP.0000130179.18176.3D
Delgado, 2005, Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction, J Heart Lung Transplant, 24, 166, 10.1016/j.healun.2003.09.043
Larson, 2006, Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus, Am J Transplant, 6, 514, 10.1111/j.1600-6143.2005.01177.x
Webster, 2006, Target of rapamycin inhibitors (sirolimus, and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials, Transplantation, 81, 1234, 10.1097/01.tp.0000219703.39149.85
Ekberg, 2007, Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, 357, 2562, 10.1056/NEJMoa067411
Meiser, 2005, First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation, Am J Transplant, 1, 827, 10.1111/j.1600-6143.2005.00757.x
Vazquez de Prada, 2006, Sirolimus in de novo heart transplant recipients with severe renal impairment, Transpl Int, 19, 245, 10.1111/j.1432-2277.2005.00258.x
Hershberger, 2005, Daclizumab to prevent rejection after cardiac transplantation, N Engl J Med, 352, 2705, 10.1056/NEJMoa032953
Mehra, 2005, A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation, J Heart Lung Transplant, 24, 1297, 10.1016/j.healun.2004.09.010
Cantarovich, 2002, Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor “holiday” in solid organ transplant patients with acute renal dysfunction, Transplantation, 73, 1169, 10.1097/00007890-200204150-00030
Potter, 2005, Long-term calcineurin inhibitor “holiday” using daclizumab in a heart transplant patient with acute renal dysfunction, J Heart Lung Transplant, 24, 1126, 10.1016/j.healun.2004.10.002
Cantarovich, 2007, Renal protective strategies in heart transplant patients, Curr Opin Cardiol, 22, 133, 10.1097/HCO.0b013e32801466e4
Aleksic, 2000, Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine, Transplantation, 69, 1586, 10.1097/00007890-200004270-00012
Tedoriya, 2002, Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil, J Heart Lung Transplant, 21, 976, 10.1016/S1053-2498(02)00422-9
Baryalei, 2003, Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine, Transplant Proc, 35, 1539, 10.1016/S0041-1345(03)00360-9
Zuckermann, 2001, Benefit of mycophenolate-mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation, J Heart Lung Transplant, 20, 163, 10.1016/S1053-2498(00)00296-5
Sanchez, 2004, Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine, Transplant Proc, 36, 2823, 10.1016/j.transproceed.2004.09.035
Boyer, 2005, Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil, Transplantation, 79, 1405, 10.1097/01.TP.0000156990.11135.60
Manito, 2005, Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule, Clin Transplant, 19, 304, 10.1111/j.1399-0012.2005.00238.x
Al-Aly, 2006, Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity, Nephrology, 11, 151, 10.1111/j.1440-1797.2006.00548.x
Angermann, 2004, Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study, Eur Heart J, 25, 1626, 10.1016/j.ehj.2004.06.032
Hamour, 2007, Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients, Transplantation, 83, 570, 10.1097/01.tp.0000253883.52525.7c
Meiser, 2007, Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious, J Heart Lung Transplant, 26, 598, 10.1016/j.healun.2007.03.011
Lehmkuhl, 2007, Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients, J Heart Lung Transplant, 26, 700, 10.1016/j.healun.2007.02.008
Trösch, 2004, First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation, Thorac Cardiovasc Surg, 52, 163, 10.1055/s-2004-820880
Schweiger, 2006, Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients, Transpl Immunol, 16, 46, 10.1016/j.trim.2006.02.001
Balfour, 2006, Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients, J Heart Lung Transplant, 25, 518, 10.1016/j.healun.2006.01.004
Ross, 2008, Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients, J Heart Lung Transplant, 27, 197, 10.1016/j.healun.2007.11.565
Lehmkuhl, 2005, Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure, Transplant Proc, 37, 4145, 10.1016/j.transproceed.2005.10.005
Zuckermann, 2008, Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation, J Heart Lung Transplant, 27, 141, 10.1016/j.healun.2007.08.014
Rothenburger, 2007, Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference, J Heart Lung Transplant, 26, 305, 10.1016/j.healun.2007.01.010
Cantarovich, 1999, Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients, Transplantation, 68, 10.1097/00007890-199912270-00003
Cantarovich, 1998, Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy, Clin Transplant, 12, 243
Kittleson, 2006, De novo C2 monitoring immediately after cardiac transplantation is not associated with improved renal function, J Heart Lung Transplant, 25, S127, 10.1016/j.healun.2005.11.251
Cantarovich, 2003, Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction, Clin Transplant, 17, 144, 10.1034/j.1399-0012.2003.00036.x
Barnard, 2006, Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation, J Heart Lung Transplant, 25, 564, 10.1016/j.healun.2005.12.005
Cantarovich, 2008, Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction, Transplantation, 85, 992, 10.1097/TP.0b013e318169bf43
Keogh, 2007, Everolimus in de novo heart transplant recipients six month data on cyclosporine reduction and impact on renal function, J Heart Lung Transplant, 26, S202, 10.1016/j.healun.2006.11.417
Cantarovich, 1999, Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients, Transplantation, 68, 10.1097/00007890-199912270-00003
Mathias, 2005, A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients, J Heart Lung Transplant, 24, 2137, 10.1016/j.healun.2005.04.019
Hunt, 2007, Premature Termination of a Prospective, Open Label, Randomized, Multicenter Study of Srl to Replace CNIs (CNI) in a Standard Care Regimen of CNI, MMF and Corticosteroids Early after Heart Transplantation, J Heart Lung Transplant, 26, S203, 10.1016/j.healun.2006.11.419
Snell, 2002, Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment, J Heart Lung Transplant, 21, 540, 10.1016/S1053-2498(01)00421-1
Groetzner, 2004, Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure, Transplantation, 77, 568, 10.1097/01.TP.0000103740.98095.14
Zakliczynski, 2003, Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation, Transplant Proc, 35, 2331, 10.1016/S0041-1345(03)00772-3
Lyster, 2004, Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation, Transplant Proc, 36, 3167, 10.1016/j.transproceed.2004.10.062
Bestetti, 2006, Switch from cyclosporine to sirolimus as a treatment of acute renal failure complicating cardiogenic shock in a heart transplant recipient, Int J Cardiol, 112, 83, 10.1016/j.ijcard.2006.03.081
Fernandez-Valls, 2005, Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center, Transplant Proc, 37, 4021, 10.1016/j.transproceed.2005.09.152
De Meester, 2005, Preservation of renal function after heart transplantation: initial single-center experience with sirolimus, Transplant Proc, 37, 10.1016/j.transproceed.2005.02.090
Aranda-Dios, 2006, Sirolimus experience in heart transplantation, Transplant Proc, 38, 2547, 10.1016/j.transproceed.2006.08.075
Cabezón, 2005, Sirolimus improves renal function in cardiac transplantation, Transplant Proc, 37, 1546, 10.1016/j.transproceed.2005.02.006
Moro, 2007, mTor Inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study, Transplant Proc, 39, 10.1016/j.transproceed.2007.06.048
Kushwaha, 2005, Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity, J Heart Lung Transplant, 24, 2129, 10.1016/j.healun.2005.08.015
Hunt, 2005, Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation, J Heart Lung Transplant, 24, 10.1016/j.healun.2005.02.018
Gleissner, 2006, Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy, Am J Transplant, 6, 2750, 10.1111/j.1600-6143.2006.01527.x
Rothenburger, 2007, Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months’ follow-up, J Heart Lung Transplant, 26, 250, 10.1016/j.healun.2007.01.017
Gustafsson, 2007, Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction, J Heart Lung Transplant, 26, 998, 10.1016/j.healun.2007.07.034
Raichlin, 2007, Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients, Transplantation, 84, 467, 10.1097/01.tp.0000276959.56959.69
Aliabadi, 2008, Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients, Am J Transplant, 8, 854, 10.1111/j.1600-6143.2007.02142.x
Mancini, 2003, Use of rapamycin slows progression of cardiac transplantation vasculopathy, Circulation, 108, 48, 10.1161/01.CIR.0000070421.38604.2B